These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 19954548)
1. Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo. Kitamura A; Mastumoto S; Asahina I Cancer Cell Int; 2009 Dec; 9():30. PubMed ID: 19954548 [TBL] [Abstract][Full Text] [Related]
2. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin. Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111 [TBL] [Abstract][Full Text] [Related]
3. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis. Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504 [TBL] [Abstract][Full Text] [Related]
4. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843 [TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Shepherd AR; Shepherd E; Brook NR Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259 [TBL] [Abstract][Full Text] [Related]
6. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Shapiro A; Ratliff TL; Oakley DM; Catalona WJ Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040 [TBL] [Abstract][Full Text] [Related]
7. Prosthetic Joint Infection due to Mycobacterium bovis after Intravesical Instillation of Bacillus Calmette-Guerin (BCG). Gomez E; Chiang T; Louie T; Ponnapalli M; Eng R; Huang DB Int J Microbiol; 2009; 2009():527208. PubMed ID: 20066167 [TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer. Miyazaki J; Onozawa M; Takaoka E; Yano I Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322 [TBL] [Abstract][Full Text] [Related]
9. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer. Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496 [TBL] [Abstract][Full Text] [Related]
11. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors. Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563 [TBL] [Abstract][Full Text] [Related]
12. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924 [TBL] [Abstract][Full Text] [Related]
13. A case of infectious thoracic aortic aneurysm after intravesical Bacillus Calmette-Guérin instillation therapy for a superficial bladder cancer. Koterazawa S; Watanabe J; Uemura Y; Uegaki M; Shirahase T; Taki Y Urol Case Rep; 2021 May; 36():101574. PubMed ID: 33552915 [TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Ratliff TL; Palmer JO; McGarr JA; Brown EJ Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453 [TBL] [Abstract][Full Text] [Related]
15. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model. Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462 [TBL] [Abstract][Full Text] [Related]
16. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068 [TBL] [Abstract][Full Text] [Related]
18. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653 [TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal? D'Andrea D; Gontero P; Shariat SF; Soria F Transl Androl Urol; 2019 Feb; 8(1):85-93. PubMed ID: 30976572 [TBL] [Abstract][Full Text] [Related]
20. Mycotic aortic aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic challenges. Holmes BJ; LaRue RW; Black JH; Dionne K; Parrish NM; Melia MT Int J Mycobacteriol; 2014 Mar; 3(1):60-5. PubMed ID: 26786225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]